# FORM 4

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person— Yorke Justin W			2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						(Check all applicable)				er	
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106			3. Date of Earliest Transaction (Month/Day/Year) 08/05/2021						Office	r (give title belo	ow)	Other (specify	below)	
(Street) HANOVER, MD 21076			4. If Amendment, Date Original Filed(Month/Day/Year)  6. Indiv_X_ Form							idual or Joint/Group Filing(Check Applicable Line) filed by One Reporting Person filed by More than One Reporting Person				
(City	)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									Owned	
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		Benefic Reporte (Instr. 3		ount of Securities icially Owned Following ted Transaction(s) 3 and 4)		Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	V	Amount	(A) or (D)	Price				(I) (Instr. 4)	
Common	Stock		08/05/2021		A		1,169	A	<u>(1)</u>	301,875			D	
Common	Stock									257,972			I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC
Common	Stock									248,272			I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC
Reminder:	Report on a s	separate line fo	r each class of secur	ities beneficially ov		Pers	ons who	respo	rm are	not requ	ction of inf ired to res OMB cont	spond unle	ess	2 1474 (9-02)
				Derivative Securiti		,		/		•				
Derivative Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	3A. Deemed Execution Da any	te, if Transaction Code ('ear) (Instr. 8)	5.	6. Da	converti ate Exerci Expiration nth/Day/Y	sable Date	7. T Ame Und Seco	itle and ount of lerlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form o Derivat Securit Direct ( or India	f Beneficial Ownershij (Instr. 4)

	Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
--	------	---	-----	--	---------------------	--------------------	-------	--	--	--	--	--	--

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Yorke Justin W C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X					

### **Signatures**

s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact	08/09/2021
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based restricted shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.